Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm

IF 2.7 2区 医学 Q2 PATHOLOGY
Akiko Miyagi Maeshima , Hirokazu Taniguchi , Yuka Takahashi , Yuto Kaimi , Tetsuro Ochi , Haruhi Makino , Shinichi Makita , Noriko Iwaki , Suguru Fukuhara , Wataru Munakata , Koji Izutsu
{"title":"Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm","authors":"Akiko Miyagi Maeshima ,&nbsp;Hirokazu Taniguchi ,&nbsp;Yuka Takahashi ,&nbsp;Yuto Kaimi ,&nbsp;Tetsuro Ochi ,&nbsp;Haruhi Makino ,&nbsp;Shinichi Makita ,&nbsp;Noriko Iwaki ,&nbsp;Suguru Fukuhara ,&nbsp;Wataru Munakata ,&nbsp;Koji Izutsu","doi":"10.1016/j.humpath.2024.105630","DOIUrl":null,"url":null,"abstract":"<div><p>This study aimed to analyze the heterogeneity or change in cell of origin (COO) in diffuse large B-cell lymphoma (DLBCLs) using the Hans algorithm including 156 patients with multiple DLBCL specimens. COO was detected via immunohistochemical staining for CD10, BCL6, and MUM1. The COO of the main tumor at initial diagnosis was germinal center B-cell (GCB) and non-GCB type in 50 (32%) and 106 (68%) patients, respectively. It did not change in 126 patients (81%). However, it changed in 30 patients (19%), from GCB to non-GCB in 12 patients and vice versa in 18 patients. The COO was heterogeneous or changed in 14% of simultaneous samples at other sites during the initial diagnosis, in 7% of primary refractory sites, and in 20% of samples obtained in the relapse phase other than the primary site. Changes in CD10, BCL6, and MUM1 expression were observed in 15%, 23%, and 24% samples, respectively. A low incidence of change in COO was observed in DLBCL with CD10<sup>+</sup>/BCL6<sup>+</sup>/MUM1<sup>-</sup> (4%), CD10<sup>-</sup>/BCL6<sup>-</sup>/MUM1<sup>+</sup> (3%), and CD10<sup>-</sup>/BCL6<sup>-</sup>/MUM1<sup>-</sup> (0%) patterns, whereas DLBCL with other patterns showed COO changes at rates of 20–37%. In conclusion, COO was heterogeneous or changed in 19% of DLBCL cases. The COO should be re-examined in other biopsy samples to determine the optimal treatment.</p></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"151 ","pages":"Article 105630"},"PeriodicalIF":2.7000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0046817724001394","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to analyze the heterogeneity or change in cell of origin (COO) in diffuse large B-cell lymphoma (DLBCLs) using the Hans algorithm including 156 patients with multiple DLBCL specimens. COO was detected via immunohistochemical staining for CD10, BCL6, and MUM1. The COO of the main tumor at initial diagnosis was germinal center B-cell (GCB) and non-GCB type in 50 (32%) and 106 (68%) patients, respectively. It did not change in 126 patients (81%). However, it changed in 30 patients (19%), from GCB to non-GCB in 12 patients and vice versa in 18 patients. The COO was heterogeneous or changed in 14% of simultaneous samples at other sites during the initial diagnosis, in 7% of primary refractory sites, and in 20% of samples obtained in the relapse phase other than the primary site. Changes in CD10, BCL6, and MUM1 expression were observed in 15%, 23%, and 24% samples, respectively. A low incidence of change in COO was observed in DLBCL with CD10+/BCL6+/MUM1- (4%), CD10-/BCL6-/MUM1+ (3%), and CD10-/BCL6-/MUM1- (0%) patterns, whereas DLBCL with other patterns showed COO changes at rates of 20–37%. In conclusion, COO was heterogeneous or changed in 19% of DLBCL cases. The COO should be re-examined in other biopsy samples to determine the optimal treatment.

使用 Hans 算法确定弥漫大 B 细胞淋巴瘤的异质性或起源细胞的变化。
本研究旨在利用汉斯算法分析弥漫大B细胞淋巴瘤(DLBCL)中起源细胞(COO)的异质性或变化,研究对象包括156例具有多个DLBCL标本的患者。COO通过CD10、BCL6和MUM1的免疫组化染色检测。最初诊断时主要肿瘤的COO为生殖中心B细胞(GCB)型和非GCB型的患者分别有50人(32%)和106人(68%)。126名患者(81%)的主肿瘤组织未发生变化。但有 30 例患者(19%)的 COO 发生了变化,其中 12 例患者的 COO 从 GCB 型变为非 GCB 型,18 例患者的 COO 从 GCB 型变为非 GCB 型。在初诊时同时采集的其他部位样本中,有 14% 的 COO 存在异质性或发生了变化;在原发难治部位样本中,有 7% 的 COO 存在异质性或发生了变化;在复发阶段采集的样本中,有 20% 的 COO 存在异质性或发生了变化。CD10、BCL6和MUM1表达发生变化的样本分别占15%、23%和24%。在具有 CD10+/BCL6+/MUM1-(4%)、CD10-/BCL6-/MUM1+(3%)和 CD10-/BCL6-/MUM1-(0%)模式的 DLBCL 中,观察到 COO 变化的发生率较低,而具有其他模式的 DLBCL 出现 COO 变化的比例为 20-37%。总之,在19%的DLBCL病例中,COO存在异质性或发生了变化。应在其他活检样本中重新检查 COO,以确定最佳治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human pathology
Human pathology 医学-病理学
CiteScore
5.30
自引率
6.10%
发文量
206
审稿时长
21 days
期刊介绍: Human Pathology is designed to bring information of clinicopathologic significance to human disease to the laboratory and clinical physician. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to the understanding of human diseases. Papers published concern morphologic and clinicopathologic observations, reviews of diseases, analyses of problems in pathology, significant collections of case material and advances in concepts or techniques of value in the analysis and diagnosis of disease. Theoretical and experimental pathology and molecular biology pertinent to human disease are included. This critical journal is well illustrated with exceptional reproductions of photomicrographs and microscopic anatomy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信